Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis

Atherosclerosis

15 January Jan 2014 12 years ago
  • McLeod O, Silveira A, Fredrikson GN, Gertow K, Baldassarre D, Veglia F, Sennblad B, Strawbridge RJ, Larsson M, Leander K, Gigante B, Kauhanen J, Rauramaa R, Smit AJ, Mannarino E, Giral P, Humphries SE, Tremoli E, de Faire U, Ohrvik J, Nilsson J, Hamsten A
QR Code

The present study provides further evidence of involvement of autoantibodies against native and MDA-modified apoB-100 peptide 210 in cardiovascular disease in humans and demonstrates that these associations are present already at a subclinical stage of the disease.

Go to NCBI abstract